Clinical Trial Detail

NCT ID NCT03546686
Title Peri-Operative Ipilimumab+Nivolumab and Cryoablation Versus Standard Care in Women With Triple-negative Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Cedars-Sinai Medical Center
Indications

triple-receptor negative breast cancer

Therapies

Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.